Articles related to TARGETED THERAPIES

Explore the transformative potential of antibody-drug conjugates (ADCs) in cancer therapy, offering targeted treatments with reduced side effects. Recent approvals and ongoing trials signify a significant shift towards precision medicine in oncology.

A look into the complexities of managing advanced melanoma with BRAF–MEK inhibitors, highlighting a case study where treatment-induced toxic effects posed significant diagnostic and therapeutic challenges.

In the CodeBreaK 100 study, a lower 240 mg dose of sotorasib demonstrated similar efficacy to the FDA-approved 960 mg dose in treating KRAS G12C–mutated NSCLC, with potentially fewer severe adverse events.

This study highlights repotrectinib’s remarkable efficacy in ROS1 fusion–positive NSCLC, demonstrating a notable response even in patients with the challenging ROS1 G2032R mutation, and presents a new potential standard in targeted lung cancer therapy.

In a novel approach to combat metastatic castration-resistant prostate cancer, ODM-208, targeting cytochrome P450 11A1, has shown promising results in reducing prostate-specific antigens and testosterone levels, offering new hope in a challenging therapeutic area.

The study highlights the potential of immune cell profiling in identifying PsA patients who are more challenging to treat, paving the way for personalized treatment strategies.